The Clinical Correlations of Fatigue in Patients with Sarcoidosis

Abstract

Objective: Fatigue is considered a frequent and characteristic feature of sarcoidosis. This study was designed to determine the prevalence of fatigue in patients with sarcoidosis and to determine its potential clinical correlations in relation to symptom severity. Methods: A total of 56 sarcoidosis patients were included. Data on patient demographics, anthropometrics, disease characteristics, pulmonary function tests, 6-min walking distance (6MWD), blood biochemistry and hemogram findings were retrieved from hospital records. Psychometric instruments involved the fatigue assessment scale (FAS), Beck Depression Inventory (BDI) and Short Form-36 (SF-36) for health-related QOL (HRQOL). Results: Mean±SD patient age was 50.9±11.9 years. Of 56 patients, 44 were females and 12 were males. When compared to FAS score <22 and FAS score ≥22-34 subgroups, FAS score ≥35 (severe fatigue) subgroup was associated with significantly higher patient age and significantly lower SF-36 physical health scores. Total FAS scores were correlated positively with age (r=0.349, p=0.008) and BDI scores (r=0.515, p<0.001), while negatively with MIP (r=-0.321, p=0.019) and SF-36 physical health (r=-0.402, p=0.003) and mental health (r=-0.351, p=0.009) scores. BDI score (OR 1.146, 95% CI: 1.020 to 1.288, p=0.021) was determined to be the single independent predictor of the increased likelihood of a patient with sarcoidosis having FAS score ≥22. Conclusions: Our findings emphasize that deterioration in respiratory functions may contribute to the development of fatigue among sarcoidosis patients, and besides the fatigue, depressive symptoms and anxiety should also be an integral part of the multidisciplinary management of sarcoidosis patients.

Keywords

• Fatigue Assessment Scale (FAS)
• fatique
• health quality
• sarcoidosis

Sarkoidoz Hastalarında Yorgunluğu Etkileyen Klinik Etkenler

Abstract

Amaç: Yorgunluk, sarkoidozun sık ve karakteristik bir özelliği olarak kabul edilir. Bu çalışma, sarkoidozlu hastalarda yorgunluk prevalansını belirlemek ve semptom şiddeti ile ilişkili potansiyel klinik korelasyonlarını belirlemek için tasarlanmıştır. Gereç ve Yöntem: Toplam 56 sarkoidoz hastası dahil edildi. Hastane kayıtlarından hasta demografisi, antropometri, hastalık özellikleri, solunum fonksiyon testleri, 6 dakikalık yürüme mesafesi (6DYM), kan biyokimyası ve hemogram bulgularına ilişkin veriler elde edildi. Psikometrik araçlar, sağlıkla ilgili yaşam kalitesi (HRQOL) için yorgunluk değerlendirme ölçeği (FAS), Beck Depresyon Ölçeği (BDÖ) ve Kısa Form-36 (SF-36) kullanıldı. Bulgular: Ortalama ± SS hasta yaşı 50.9 ± 11.9 yıldı. 56 hastanın 44'ü kadın, 12'si erkekti. FAS skoru <22 ve FAS skoru ≥22-34 alt grupları ile karşılaştırıldığında, FAS skoru ≥35 (şiddetli yorgunluk) alt grubu, daha yüksek hasta yaşı (p = 0.037) ve anlamlı olarak daha düşük SF-36 fiziksel sağlık skorları (p = 0.029 ) ile anlamlı bulundu. Toplam FAS skorları yaş (r = 0.349, p = 0.008) ve BDÖ skorları (r = 0.515, p <0.001) ile pozitif korelasyon gösteriyor iken; MIP (r = -0.321, p = 0.019) ve SF-36 fiziksel sağlık (r = -0.402, p = 0.003) ve mental sağlık(r = -0.351, p = 0.009) puanları sağlık ile negatif korelasyon gösteriyordu. BDÖ skorunun (OR 1.146,% 95 CI: 1.020 - 1.288, p = 0.021), sarkoidoz hastalarının FAS skorunun ≥22 olması olasılığının artmasının tek bağımsız prediktörü olduğu belirlendi. Sonuç: Bulgularımız, solunum fonksiyonlarındaki bozulmanın sarkoidoz hastalarında yorgunluğun gelişimine katkıda bulunabileceğini ve yorgunluğun yanı sıra depresif belirtiler ve anksiyetenin sarkoidoz hastalarının multidisipliner yönetiminin ayrılmaz bir parçası olması gerektiğini vurgulamaktadır.

Keywords

• Sarkoidoz
• Yorgunluk değerlendirme ölçeği (YDÖ)
• yorgunluk
• yaşam kalitesi

References

1. 1. Hunninghake G.W, Costabel U, Ando M, Baughman R, Cordier, J.F, du Bois R et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc. Diffuse Lung Dis. 1999;16(2):149-73.
2. 2. Yıldız Gülhan P, Güleç Balbay E, Erçelik M, Yıldız Ş, Yılmaz MA. Is sarcoidosis related to metabolic syndrome and insulin resistance? Aging Male. 2020. 23 (1), 53-8 .
3. 3. Bahmer T, Watz H, Develaska M, Waschki B, Rabe KF, Magnussen H et al. Physical Activity and Fatigue in Patients with Sarcoidosis. Respiration. 2018;95(1):18–26.
4. 4. Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M: Predictors of fatigue in sarcoidosis: the value of exercise testing. Respir Med. 2016;116:49-54.
5. 5. Cho PSP, Vasudevan S, Maddocks M, Spinou A, Chamberlain Mitchell S, Wood C et al. Physical Inactivity in Pulmonary Sarcoidosis. Lung. 2019 Jun;197(3):285-93.
6. 6. Górski W, Piotrowski WJ. Fatigue syndrome in sarcoidosis. Pneumonol Alergol Pol. 2016; 84(4):244–50.
7. 7. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006;130:989–94.
8. 8. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255-263.

9. 9. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004;9(Pt 3):279–91.
10. 10. Beck AT. An inventory for measuring depression. Arch Gen Psychiatry .1961;4:561-71.
11. 11. Górski W, Mokros Ł, Kumor-Kisielewska A, Pietras T, Piotrowski WJ. The utility of selected questionnaires in the assessment of fatigue, depression and health quality in post-sarcoidosis fatigue syndrome. Adv Respir Med 2017;85(6):313-21.
12. 12. Goracci A, Fagiolini A, Martinucci M, Calossi S, Rossi S, Santomauro T, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry.2008;30(5):441–445.
13. 13. Kleijn WPE, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013;18(2):439–52.
14. 14. Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager H Jr, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329–34.
15. 15. Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in the Netherlands: an epidemiological study. Neth J Med. 1998;53(2):53–60.
16. 16. De Vries J, Van Heck GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health 1999;30(2):99–114.
17. 17. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res. 1993;2(6):451–9.
18. 18. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-Related Quality of Life of Persons With Sarcoidosis. Chest. 2004;125(3):997-1004.
19. 19. Sharma OP. Fatigue and sarcoidosis. Eur Respir J. 1999;13(4):713-4.
20. 20. Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D. Cytokine production and fatigue in patients with chronic fatigue syndrome in response to exercise. Clin Infect Dis. 1994;18 Suppl 1:142-6.
21. 21. Peterson PK, Sirr SA, Grammith FC, Schenck CH, Pheley AM, Shuxian H, et al.Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. Clin Diagn Lab Immunol. 1994;1(2): 222–6.
22. 22. Baydur A, Alavy B, Nawathe A, et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J. 2011;5(3):156-64.
23. 23. Karadallı MN, Boşnak-Güçlü M, Burcu Camcıoğlu C, Kokturk N, Haluk Türktaş H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respiratory Care.2016;61(4):483-94.
24. 24. Marcellis R, Lenssen A, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628–34.
25. 25. Jamal MM, CiLursu AH, Hoffman EL. Sarcoidosis presenting as acute myositis: report and review of literature. J Rheumatol. 1988;15(12):1868–78.
26. 26. Ost D, Yeldandi A, Cugell D. Acute sarcoid myositis with respiratory muscle involvement: case report and review of the literature. Chest 1995;107(3):879–82.
27. 27. Brancaleone P, Perez T, Robin S, Neviere R, Wallaert B. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(3):219-7.
28. 28. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32–8.
29. 29. Baughman RP, Lower EE. Six minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med. 2007;13(5):439-44.
30. 30. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007;132(1):207-13.
31. 31. Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22(3):235.
32. 32. Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial. Pain Symptom Manage. 2013;45(2):159–69.
33. 33. Fouchier SM, Möller GM, Van Santen-Hoeufft M, Faber CG, Smeenk FW, Drent M. . Successful treatment with infliximab of a patient with refractory sarcoidosis. Ned Tijdschr Geneeskd 2004;148(49):2446–50.